Evidence map›Paper›PMID 22198386›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2012

EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF.

Gabi Tarcic, Roi Avraham, Gur Pines, Ido Amit, Tal Shay, Yiling Lu, Yaara Zwang, Menachem Katz, Nir Ben-Chetrit, Jasmine Jacob-Hirsch and 6 more

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 134 citations in OpenAlex.

  1. Platelet-derived growth factor receptor alpha regulates fetal testis differentiation via an ERK-CREB axis.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Gabi TarcicDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Roi Avraham
Gur Pines
Ido Amit
Tal Shay
Yiling Lu
Yaara Zwang
Menachem Katz
Nir Ben-Chetrit
Jasmine Jacob-Hirsch
Laura Virgilio
Gideon Rechavi
George Mavrothalassitis
Gordon B Mills
Eytan Domany
Yosef Yarden
Weizmann Institute of Science · ILThe University of Texas MD Anderson Cancer Center · USUniversity of Crete · GRCancer Research Center · USRockefeller University · USSheba Medical Center · IL

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0M
Next generation strategies to intercept ErbB signalingR37CA072981 · NCI · WEIZMANN INSTITUTE OF SCIENCE · PI YARDEN, YOSEF · 2005 to 2014
$2.3M
LATERAL VERSUS VERTICAL SIGNALING BY ERBB2 ONCOPROTEINR01CA072981 · NCI · WEIZMANN INSTITUTE OF SCIENCE · PI YARDEN, YOSEF NONE · 1997 to 2004
$953k
The PI3K/PTEN/AKT Signal Transduction Cascade in Breast CancerK23CA121994 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GONZALEZ-ANGULO, ANA M. · 2006 to 2010
$680k
Funtional Proteomics and Response to Preoperative Theraphy in Breast CancerR21CA120248 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GONZALEZ-ANGULO, ANA M. · 2006 to 2007
$260k
NCI NIH HHS CA072981NCI NIH HHS CA120248-01NCI NIH HHS CA121994-01NCI NIH HHS K23 CA121994NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA098258NCI NIH HHS R01 CA072981NCI NIH HHS R21 CA120248NCI NIH HHS R37 CA072981
6 · The paper itself

Abstract

The signaling pathways that commit cells to migration are incompletely understood. We employed human mammary cells and two stimuli: epidermal growth factor (EGF), which induced cellular migration, and serum factors, which stimulated cell growth. In addition to strong activation of ERK by EGF, and AKT by serum, early transcription remarkably differed: while EGF induced early growth response-1 (EGR1), and this was required for migration, serum induced c-Fos and FosB to enhance proliferation. We demonstrate that induction of EGR1 involves ERK-mediated down-regulation of microRNA-191 and phosphorylation of the ETS2 repressor factor (ERF) repressor, which subsequently leaves the nucleus. Unexpectedly, knockdown of ERF inhibited migration, which implies migratory roles for exported ERF molecules. On the other hand, chromatin immunoprecipitation identified a subset of direct EGR1 targets, including EGR1 autostimulation and SERPINB2, whose transcription is essential for EGF-induced cell migration. In summary, EGR1 and the EGF-ERK-ERF axis emerge from our study as major drivers of growth factor-induced mammary cell migration.

Indexed as

Cell LineCell MovementCell ProliferationEarly Growth Response Protein 1Epidermal Growth FactorExtracellular Signal-Regulated MAP KinasesFemaleGene Expression ProfilingHumansMammary Glands, HumanMicroarray AnalysisMicroRNAsProteomeRepressor ProteinsSignal TransductionTwo-Hybrid System TechniquesEarly Growth Response Protein 1EGR1 protein, humanEpidermal Growth FactorERF protein, humanExtracellular Signal-Regulated MAP KinasesMicroRNAsMIRN191 microRNA, humanProteomeRepressor Proteins

Identifiers

PMID22198386
PMCPMC3316897
OpenAlexW2059562044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.